Addendum

Vutrisiran (hereditary transthyretin amyloidosis with polyneuropathy) – Addendum to Commission A22-114

Status
Status: Commission completed
Project no.
A23-12
Last updated

Report documents

  1. Addendum

    Vutrisiran (hereditary transthyretin amyloidosis with polyneuropathy) – Addendum to Commission A22-114

    published on
    Document type
    PDF document, 398 kB, EN, not accessible

Dossier assessment

Indication:

Adults with hereditary transthyretin-mediated amyloidosis with stage 1 or stage 2 polyneuropathy

Result of dossier assessment:

Unchanged after addendum: hint of minor added benefit

Additional information

Federal Joint Committee (G-BA)

2023-04-06 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A23-12
Commission
Commission awarded on 21.02.2023 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Head and nerves
Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

Connected Projects

  1. Dossier assessment

    Vutrisiran (hereditary transthyretin amyloidosis) – Benefit assessment according to § 35a SGB V

    Project no.
    A22-114
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form